All In Biotech

Drug Trial Radar · NCT07649525

Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level

iFIT (UK-MRA Myeloma XVIII): Immunotherapy Approaches Adapted for Fitness in Newly Diagnosed Transplant Ineligible Patients With Myeloma

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,226 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,226

Planned (sponsor's estimate)

Start

Jul 3, 2026

Primary completion

Jun 2033

Study completion Jun 2037

Sponsor

Lead sponsor
University of LeedsAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cancer Research UK; Blood Cancer UK; Johnson & Johnson
First posted
Jun 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

iFIT is a trial for newly diagnosed transplant-ineligible patients with the bone marrow cancer myeloma. These patients are generally older and have a lower level of fitness than others. Patients can take part if their doctor would otherwise recommend the standard NHS treatment daratumumab, lenalidomide and dexamethasone (DRd). After six months of DRd, the subsequent treatment a patient receives in iFIT is based on two factors: the patient's fitness level and treatment response. The trial compares different treatment strategies to determine whether outcomes can be improved for specific patient groups.

Conditions

  • Multiple Myeloma (MM)
  • Plasma Cell Leukemia (PCL)

Interventions

  • DaratumumabDrug

    Participants will receive daratumumab by subcutaneous injection. Each cycle is 28 days.

  • LenalidomideDrug

    Taken orally as capsules. Each cycle is 28 days. Dose can be adjusted for frailty and renal function.

  • DexamethasoneDrug

    Taken as oral tablets, oral solution, or given by IV. Each cycle is 28 days. Dose can be adjusted for frailty and renal function.

  • TeclistamabDrug

    Participants will receive teclistamab by subcutaneous injection. Each cycle is 28 days.

  • TalquetamabDrug

    Participants will receive talquetamab by subcutaneous injection. Each cycle is 28 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. iFIT1: Progression-free survival (PFS)Time frame: From iFIT1 randomisation to PFS event, assessed up to a maximum of 10.5 years post-randomisation.
  2. iFIT2: Event-free survival (EFS)Time frame: From iFIT2 randomisation to EFS event, assessed up to a maximum of 6.5 years post-randomisation.
  3. iFIT3: Progression-free survival (PFS) and participant-reported overall health and quality of life (QoL) - co-primary outcomesTime frame: PFS: from iFIT3 randomisation to PFS event, assessed up to a maximum of 10.5 years post-randomisation. QoL: measured at the start of cycle 1 and after 6 28-day cycles of DRd induction, and further timepoints up to 30 months post-iFIT3 randomisation.

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Bristol Haematology and Oncology Centre

    Bristol, United Kingdom · Not yet recruiting

  • Eastbourne District General Hospital

    Eastbourne, United Kingdom · Not yet recruiting

  • St James University Hospital

    Leeds, United Kingdom · Not yet recruiting

  • The Clatterbridge Cancer Centre - Liverpool

    Liverpool, United Kingdom · Recruiting

  • The Royal Marsden Hospital

    London, United Kingdom · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.